Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study
- Citation:
- Br J Haematol vol 171 (3) 373-377
- Year:
- 2015
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 5
- Parents:
- 816
- Children:
- None
- Pharmas:
- Grants:
- U10 CA047577, CA33601, CA77597, CA04457, CA101140, CA77406, CA47577, CA29165, U10 CA045564, CA41287, U10 CA045808, CA03927, U10 CA031946, U10 CA033601, CA59518, U10 CA180821, CA26806, U10 CA077597, CA45808, U10 CA059518, U10 CA045418, U10CA180882, U10 CA077440, CA16450, U10 CA101140, CA77440, U10 CA041287, CA45564, U10 CA047559, CA04326, U10 CA180882, CA47559, CA45418, U10CA180821, CA31946, U10 CA003927
- Corr. Author:
- Authors:
- Peter M. Voorhees Robert Z. Orlowski Flora Mulkey Peter Watson Susan Geyer Ben L. Sanford Elizabeth Bennett Asher A. Chanan-Khan Clara D. Bloomfield Richard A. Larson
- Networks:
- LAPS-IL057, LAPS-MN026, LAPS-NC010, LAPS-TX035, NC002, NC012
- Study
- CALGB-10301
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Multiple myeloma, proteasome inhibitors, anthracyclines, international staging system